Cytomegalovirus and glioblastoma; controversies and opportunities

Journal of Neuro-Oncology

Volumn 123, Issue 3, 2015, Pages 465-471

  Lawler, Sean E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cytomegalovirus; Glioblastoma; Immunotherapy

Indexed keywords

CIDOFOVIR; CYTOMEGALOVIRUS ANTIGEN PP65; DENDRITIC CELL VACCINE; GENOMIC DNA; MESSENGER RNA; PLACEBO; VALGANCICLOVIR; VIRUS ANTIGEN; VIRUS PROTEIN;

ABSENCE OF SIDE EFFECTS; ADOPTIVE TRANSFER; ANTIGEN DETECTION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CYTOMEGALOVIRUS; DISEASE ASSOCIATION; DISEASE MODEL; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; GLIOBLASTOMA; HUMAN; IN VITRO STUDY; MOUSE; NEUROSURGERY; NEXT GENERATION SEQUENCING; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC ERROR; VIRUS REPLICATION; ANIMAL; BRAIN NEOPLASMS; GENETICS; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTIGENS, VIRAL; BRAIN NEOPLASMS; CYTOMEGALOVIRUS; GLIOBLASTOMA; HUMANS; MICE;

EID: 84937518799     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-1734-0     Document Type: Review

References (55)

1. zur Hausen H (2009) Papillomaviruses in the causation of human cancers—a brief historical account. Virology 384(2):260–265
2. Martin D, Gutkind JS (2008) Human tumor-associated viruses and new insights into the molecular mechanisms of cancer. Oncogene 27(Suppl 2):S31–S42
3. Cobbs et al (2002) Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 62(12):3347–3350
4. Mitchell DA et al (2008) Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol 10(1):10–18
5. Scheurer ME et al (2008) Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol 116(1):79–86
6. Rahbar A et al (2013) Human cytomegalovirus infection levels in glioblastoma multiforme are of prognostic value for survival. J Clin Virol 57(1):36–42
7. Libard S et al (2014) Human cytomegalovirus tegument protein pp65 is detected in all intra-and extra-axial brain tumors independent of the tumour type or grade. PLoS ONE 9(9):e108861
8. Bhattacharjee B, Renzette N, Kowalik TE (2012) Genetic analysis of cytomegalovirus in malignant gliomas. J Virol 86(12):6815–6824
9. Ranganathan P et al (2012) Significant association of multiple human cytomegalovirus genomic loci with glioblastoma multiforme samples. J Virol 86(2):854–864
10. Price RL et al (2013) Cytomegalovirus contributes to glioblastoma in the context of tumor suppressor mutations. Cancer Res 73(11):3441–3450
11. Cobbs CS (2013) Cytomegalovirus and brain tumor: epidemiology, biology and therapeutic aspects. Curr Opin Oncol 25(6):682–688
12. Ludwig A, Hengel H (2009) Epidemiological impact and disease burden of congenital cytomegalovirus infection in Europe. Euro Surveill 14(9):26–32
13. Mustakangas P et al (2000) Human cytomegalovirus seroprevalence in three socioeconomically different urban areas during the first trimester: a population-based cohort study. Int J Epidemiol 29(3):587–591
14. Staras SAS et al (2006) Seroprevalence of cytomegalovirus infection in the United States, 1988–1994. Clin Infect Dis 43(9):1143–1151
15. Murphy E, Shenk T (2008) Human cytomegalovirus genome. Curr Top Immunol 325:1–19
16. Dölken L, Pfeffer S, Koszinowski UH (2009) Cytomegalovirus microRNAs. Virus Genes 38(3):355–364
17. Plachter B, Sinzger C, Jahn G (1996) Cell types involved in replication and distribution of human cytomegalovirus. Adv Virus Res 46:195–261
18. Taylor-Wiedeman J et al (1991) Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol 72(9):2059–2064
19. Luo MH et al (2010) Human cytomegalovirus infection causes premature and abnormal differentiation of human neural progenitor cells. J Virol 84(7):3528–3541
20. Cobbs CS et al (2007) Human cytomegalovirus induces cellular tyrosine kinase signaling and promotes glioma invasiveness. J Neurooncol 85(3):271–280
21. Straat K et al (2009) Activation of telomerase by human cytomegalovirus. J Natl Cancer Inst 101(7):488–497
22. Soroceanu L, Akhavan A, Cobbs CS (2008) Platelet-derived growth factor-a receptor activation is required for human cytomegalovirus infection. Nature 455(18):391–396
23. Slinger E et al (2010) HCMV-encoded chemokine receptor US28 mediates proliferative signaling through the IL-6-STAT3 axis. Sci Signal 3(133):ra58
24. Dziurzynski K et al (2011) Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin Cancer Res 17(14):4642–4649
25. Price RL et al (2012) Cytomegalovirus infection leads to pleomorphic rhabdomyosarcomas in Trp53+/− mice. Cancer Res 72(22):5669–5674
26. Taher C et al (2013) High prevalence of human cytomegalovirus proteins and nucleic acids in primary breast cancer and metastatic sentinel lymph nodes. PLoS ONE 8(2):e56795
27. Baryawno N et al (2011) Detection of human cytomegalovirus in medulloblastoma reveals a potential therapeutic target. J Clin Invest 121(10):4043–4055
28. Lau et al (2005) Lack of association of cytomegalovirus with human brain tumors. Mod Pathol 18(6):838–843
29. Poltermann S et al (2006) Lack of association of herpesviruses with brain tumors. J Neuro Virol 12(2):90–99
30. Baumgarten P et al (2014) Human cytomegalovirus infection in tumor cells of the nervous system is not detectable with standardized pathologico-virological diagnostics. Neuro Oncol 16(11):1469–1477
31. Hellstrand K, Martner A, Bergstrom T (2013) Valganciclovir in patients with glioblastoma. New Engl J Med 369(21):2066
32. Tang KW et al (2013) The landscape of viral expression and host gene fusion and adaptation in human cancer. Nat Commun 4:2513
33. Renzette N et al (2011) Extensive genome-wide variability of human cytomegalovirus in congenitally infected infants. PLoS Pathog 7:e1001344
34. Dziurzynski K et al (2012) Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol 14(3):246–255
35. Huse JT, Aldape K (2014) CMV and glioma—are we there yet? Neuro Oncol 16(11):1433–1434
36. Cobbs C (2014) Response to “Human cytomegalovirus infection in tumor cells of the nervous system is not detectable with standardized pathologico-virological diagnostics”. Neuro Oncol 14(3):1435–1436
37. Stragliotto G et al (2013) Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus positive glioblastoma: a randomized, double-bind, hypothesis generating study. Int J Cancer 133(5):1204–1213
38. Soderberg-Naucler C, Rahbar A, Stragliotto G (2013) Survival in patients with glioblastoma treated with valganciclovir. New Engl J Med 369(10):985–986
39. Wrensch M et al (2001) Prevalence of antibodies to four herpesviruses among adults with glioma and controls. Am J Epidemiol 154(2):161–165
40. Soderberg-Naucler C, Peredo I, Stragliotto G (2013) Valganciclovir in patients with glioblastoma. New Engl J Med 369(21):2066–2067
41. Liu C-J, Hu Y-W (2014) Immortal time bias in retrospective analysis: is there a survival benefit in patients with glioblastoma who received prolonged treatment of adjuvant valganciclovir? Int J Cancer 135(1):250–251
42. Soderberg-Naucler C et al (2014) Use of Cox regression with treatment status as a time-dependent covariate to re-analyze survival benefit excludes immortal time bias effect in patients with glioblastoma who received prolonged adjuvant treatment with valganciclovir. Int J Cancer 135(1):248–249
43. Wick W, Wick A, Platten M (2014) Good maths is needed to understand CMV data in glioblastoma. Int J Cancer 134(12):2991–2992
44. Weller M, Soffietti R, Brada M (2014) The legend of cytomegalovirus and glioblastoma lives on. Neuro Oncol 16(1):166
45. Wick W, Platten M (2014) CMV infection and glioma, a highly controversial concept struggling in the clinical arena. Neuro Oncol 16(3):332–333
46. Cobbs CS (2014) Does valganciclovir have a role in glioblastoma therapy? Neuro Oncol 16(3):330–331
47. Hadaczek P et al (2013) Cidofovir: a novel antitumor agent for glioblastoma. Clin Cancer Res 19(23):6473–6483
48. Schuessler A, Walker DG, Khanna R (2014) Cytomegalovirus as a novel target for immunotherapy of glioblastoma multiforme. Front Oncol 4:275
49. Nair SK, Sampson JH, Mitchell DA (2014) Immunological targeting of cytomegalovirus for glioblastoma therapy. Oncoimmunology 3:e29289
50. Nair SK et al (2014) Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells. Clin Cancer Res 20(X):2684–2694
51. Prins RM, Cloughesy TF, Liau LM (2008) Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med 359(5):539–541
52. Crough T et al (2012) Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme. Immunol Cell Biol 90(9):872–880
53. Ghazi et al (2012) Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother 35(2):159–168
54. Schuessler A et al (2014) Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res 74(13):3466–3476
55. Wadman M (2013) NIH mulls rules for validating key results. Nature 500(7560):14–16